Study of EV for Recurrent Endometrial Carcinoma

This study is testing a drug called enfortumab vedotin in up to 12 patients with advanced endometrial (uterine) cancer that has worsened after previous treatments, including immunotherapy. The goal is to see how well the drug works and how safe it is. Patients will be treated for up to one year and followed over time to monitor their health and response to the treatment.

Trial Details

NCT ID
NCT07139977
Phase
PHASE2
Sponsor
William Bradley
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Enfortumab Vedotin
Locations (sample)
  • Milwaukee, Wisconsin, United States|43.0389,-87.90647

Key Eligibility Criteria

  • Female patient of age ≥18 years.
  • Recurrent and progressive endometrial cancer, all stages at primary diagnosis. The histology types will be pending the preclinical assessments, but…
  • Endometrioid endometrial carcinoma
  • Serous endometrial carcinoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →